Global Expertise ACM Global Central Laboratory is a mid-sized, global central lab with 400+ staff and a broad menu of safety and specialty tests for clinical trials, suggesting opportunities to partner on large multinational studies or expansion into new therapeutic areas.

High Throughput With an analytical team performing 13 million tests annually across more than 1,500 tests, ACM demonstrates capacity to handle high-volume trial work and complex testing regimes, a selling point for sponsors with sizeable study pipelines.

Therapeutic Focus Past and ongoing activity around infectious disease testing, COVID-19 vaccine studies, and Smarter Testing for infectious disease indicates readiness to support vaccine and therapeutic trials, presenting cross-sell potential into infectious disease portfolios.

Strategic Growth Historic growth through acquisition (DrugScan Inc.) and diversified service lines position ACM as a potential partner for sponsors seeking integrated central lab services, toxicology, and diagnostic lab capabilities within a single vendor.

Emerging Enterprise Revenue is reported as under one million, highlighting a potential upsell opportunity with mid-to-large sponsor pipelines and opportunities to standardize pricing and service level agreements as the company scales.